Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells

Journal of Immunology

Volumn 183, Issue 9, 2009, Pages 5654-5661

  Tigno Aranjuez, Justine T ^a   Jaini, Ritika ^c   Tuohy, Vincent K ^a,c   Lehmann, Paul V ^a,b   Tary Lehmann, Magdalena ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Cellular Technology Limited   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 17; NEUTRALIZING ANTIBODY; PROTEOLIPID PROTEIN;

ACTIVE IMMUNIZATION; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CPG ISLAND; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSFECTION; HYPERSENSITIVITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TH17 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CPG ISLANDS; DNA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FREUND'S ADJUVANT; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY;

EID: 77954170923     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900645     Document Type: Article

References (49)

1. Parish, I. A., and W. R. Heath. 2008. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol. Cell Biol. 86: 146-152.
2. Ohashi, P. S. 2002. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat. Rev. Immunol. 2: 427-438. (Pubitemid 37328750)
3. Pordeus, V., M. Szyper-Kravitz, R. A. Levy, N. M. Vaz, and Y. Shoenfeld. 2008. Infections and autoimmunity: a panorama. Clin. Rev. Allergy Immunol. 34: 283-299.
4. Levine, S., and R. Sowinski. 1973. Experimental allergic encephalomyelitis in inbred and outbred mice. J. Immunol. 110: 139-143.
5. Ichikawa, H. T., L. P. Williams, and B. M. Segal. 2002. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169: 2781-2787.
6. Segal, B. M., J. T. Chang, and E. M. Shevach. 2000. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164: 5683-5688.
7. Segal, B. M., D. M. Klinman, and E. M. Shevach. 1997. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 158: 5087-5090.
8. Swanborg, R. H. 2001. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol. Rev. 184: 129-135.
9. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17: 138-146.
10. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr. Opin. Immunol. 8: 336-342.
11. H1 clones. J. Immunol. 138: 3688-3694.
12. McRae, B. L., M. K. Kennedy, L. J. Tan, M. C. Dal Canto, K. S. Picha, and S. D. Miller. 1992. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol. 38: 229-240.
13. Clatch, R. J., H. L. Lipton, and S. D. Miller. 1986. Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J. Immunol. 136: 920-927.
14. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156: 5-7.
15. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181: 381-386.
16. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
17. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
18. Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Ag-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17: 375-387.
19. Mills, K. H. 2008. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 38: 2636-2649.
20. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566-573.
21. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186: 1623-1631.
22. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
23. Andersson, A., M. Isaksson, J. Wefer, A. Norling, A. Flores-Morales, F. Rorsman, O. Kampe, R. A. Harris, and A. Lobell. 2008. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis. PLoS ONE. 3: e3682.
24. Boccaccio, G. L., F. Mor, and L. Steinman. 1999. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis. Int. Immunol. 11: 289-296.
25. Lobell, A., R. Weissert, S. Eltayeb, C. Svanholm, T. Olsson, and H. Wigzell. 1999. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J. Immunol. 163: 4754-4762. (Pubitemid 29501237)
26. Lobell, A., R. Weissert, M. K. Storch, C. Svanholm, K. L. de Graaf, H. Lassmann, R. Andersson, T. Olsson, and H. Wigzell. 1998. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 187: 1543-1548.
27. Schmued, L., and W. Slikker, Jr. 1999. Black-gold: a simple, high-resolution histochemical label for normal and pathological myelin in brain tissue sections. Brain Res. 837: 289-297.
28. Yip, H. C., A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. 1999.Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162: 3942-3949.
29. H17 and regulatory T cells. Nature 441: 235-238.
30. Stern, B. V., B. O. Boehm, and M. Tary-Lehmann. 2002. Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ -dependent CD4 cell immunity. J. Immunol. 168: 6099-6105.
31. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
32. Prinz, M., F. Garbe, H. Schmidt, A. Mildner, I. Gutcher, K. Wolter, M. Piesche, R. Schroers, E. Weiss, C. J. Kirschning, et al. 2006. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116: 456-464.
33. Marta, M., A. Andersson, M. Isaksson, O. Kampe, and A. Lobell. 2008. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 38: 565-575.
34. Beste, D. J., J. Peters, T. Hooper, C. Avignone-Rossa, M. E. Bushell, and J. McFadden. 2005. Compiling a molecular inventory for Mycobacterium bovis BCG at two growth rates: evidence for growth rate-mediated regulation of ribosome biosynthesis and lipid metabolism. J. Bacteriol. 187: 1677-1684.
35. Lee, K. W., J. Jung, Y. Lee, T. Y. Kim, S. Y. Choi, J. Park, D. S. Kim, and H. J. Kwon. 2006. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. 43: 2107-2118.
36. Krug, A., A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Tolllike receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31: 3026-3037. (Pubitemid 32994554)
37. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA 93: 2879-2883.
38. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177: 1199-1204.
39. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
40. Ferwerda, G., S. E. Girardin, B. J. Kullberg, L. Le Bourhis, D. J. de Jong, D. M. Langenberg, R. van Crevel, G. J. Adema, T. H. Ottenhoff, J. W. Van der Meer, and M. G. Netea. 2005. NOD2 and Toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 1: 279-285.
41. Lyakh, L., G. Trinchieri, L. Provezza, G. Carra, and F. Gerosa. 2008. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol. Rev. 226: 112-131.
42. van Beelen, A. J., Z. Zelinkova, E. W. Taanman-Kueter, F. J. Muller, D. W. Hommes, S. A. Zaat, M. L. Kapsenberg, and E. C. de Jong. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27: 660-669.
43. Werninghaus, K., A. Babiak, O. Gross, C. Holscher, H. Dietrich, E. M. Agger, J. Mages, A. Mocsai, H. Schoenen, K. Finger, et al. 2009. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206: 89-97.
44. Mullen, G. E., R. D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M. P. Fay, A. Saul, D. Zhu, K. Rausch, et al. 2008. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3: e2940.
45. Cooper, C. L., H. L. Davis, M. L. Morris, S. M. Efler, M. A. Adhami, A. M. Krieg, D. W. Cameron, and J. Heathcote. 2004. CPG 7909, an immuno-stimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin. Immunol. 24: 693-701.
46. Cooper, C. L., H. L. Davis, M. L. Morris, S. M. Efler, A. M. Krieg, Y. Li, C. Laframboise, M. J. Al Adhami, Y. Khaliq, I. Seguin, and D. W. Cameron. 2004. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136-3143.
47. Carpentier, A., F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, et al. 2006. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 8: 60-66.
48. Leonard, J. P., B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et l. 2007. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13: 6168-6174.
49. Gupta, K., and C. Cooper. 2008. A review of the role of CpG oligodeoxynucleotides as Toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D. 9: 137-145.